These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

656 related items for PubMed ID: 7483816

  • 1. Immunotherapy with bispecific antibodies.
    Thielemans KM.
    Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
    [Abstract] [Full Text] [Related]

  • 2. Bispecific antibody therapy of two murine B-cell lymphomas.
    Demanet C, Brissinck J, Moser M, Leo O, Thielemans K.
    Int J Cancer Suppl; 1992; 7():67-8. PubMed ID: 1428409
    [Abstract] [Full Text] [Related]

  • 3. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
    Demanet C, Brissinck J, Van Mechelen M, Leo O, Thielemans K.
    J Immunol; 1991 Aug 01; 147(3):1091-7. PubMed ID: 1830596
    [Abstract] [Full Text] [Related]

  • 4. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
    Weiner GJ, Hillstrom JR.
    J Immunol; 1991 Dec 01; 147(11):4035-44. PubMed ID: 1834746
    [Abstract] [Full Text] [Related]

  • 5. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
    Demanet C, Brissinck J, Leo O, Moser M, Thielemans K.
    Cancer Res; 1994 Jun 01; 54(11):2973-8. PubMed ID: 8187084
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C, Kornacker M, Scheffold YC, Contag CH, Negrin RS.
    Cancer Res; 2002 Oct 15; 62(20):5785-91. PubMed ID: 12384539
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
    Garcia de Palazzo I, Holmes M, Gercel-Taylor C, Weiner LM.
    Cancer Res; 1992 Oct 15; 52(20):5713-9. PubMed ID: 1394194
    [Abstract] [Full Text] [Related]

  • 15. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A, Mezzanzanica D, Jung G, Wolf H, Colnaghi MI, Canevari S.
    Cancer Res; 1996 Dec 01; 56(23):5443-9. PubMed ID: 8968099
    [Abstract] [Full Text] [Related]

  • 16. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells.
    Cho BK, Roy EJ, Patrick TA, Kranz DM.
    Bioconjug Chem; 1997 Dec 01; 8(3):338-46. PubMed ID: 9177839
    [Abstract] [Full Text] [Related]

  • 17. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3xCD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells.
    Bohlen H, Manzke O, Titzer S, Lorenzen J, Kube D, Engert A, Abken H, Wolf J, Diehl V, Tesch H.
    Cancer Res; 1997 May 01; 57(9):1704-9. PubMed ID: 9135012
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
    Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, Mangold S, Rau D, Meier P, Kiener PA, Mulgrew K, Oberst MD, Hammond SA, Baeuerle PA, Kufer P.
    J Immunother; 2009 May 01; 32(4):341-52. PubMed ID: 19342971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.